Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 2571 • ACR Convergence 2025
Rare Clinically Significant Methotrexate Toxicity Despite Frequent Laboratory Abnormalities: A Population-Based Study of Methotrexate Monitoring
Griffin Reed¹, Jeffrey Yang¹, Georges El Hasbani¹, Cynthia Crowson², Hannah Langenfeld¹, Jeffrey Sparks³, Bryant England⁴, gabriela Schmajuk⁵, Kaleb Michaud⁴, John Davis¹ and Vanessa Kronzer¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Stewartvillle, MN, ³Brigham and Women's Hospital, Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Methotrexate laboratory monitoring is highly resource intensive, and recent evidence questions whether the true toxicity of methotrexate has been over-estimated. Therefore, we aimed to…
Abstract Number: 2228 • ACR Convergence 2025
COVID-19 Outcomes in Rheumatoid Arthritis Patients Prescribed Biologic vs. Conventional DMARDs: A Propensity-Matched Analysis
Chase Verdugo¹, Yazin Hindosh¹, Akram Hindosh¹, Jonathan Sayegh¹, Bassam Mitri¹, Johnny Youssef¹, Tyler On¹, Faissal Stipho² and Issa Batarseh², ¹University of Arizona College of Medicine Tucson, Tucson, AZ, ²Department of Internal Medicine, Banner University Medical Center / University of Arizona, Tucson, Arizona, Tucson, AZ
Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune disease characterized by immune system dysregulation, and it is commonly treated with either conventional or biologic Disease-Modifying Antirheumatic…
Abstract Number: 1477 • ACR Convergence 2025
Can Large Language Models Support Clinical Decision-Making in Atypical SLE? A Comparative Analysis
Beste Acar¹, Berkay Aktas¹, Oguzhan Omer Kizilkaya¹, Zekayi Kutlubay² and serdal Ugurlu³, ¹Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Dermatology, Istanbul, Turkey, Istanbul, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: This study evaluates the contributions of large language models (LLMs) in clinical decision-making for atypical presentations of systemic lupus erythematosus (SLE). It focuses on…
Abstract Number: 1322 • ACR Convergence 2025
High Rheumatoid Factor Titers and Biologic Persistence in RA: Beyond TNF Inhibitors
Sara Salas Santamaría¹, Marta Chao Moreira², Manuel Juárez³, Marta Novella-Navarro², Pilar Nozal², Ana Martínez², Carolina Tornero⁴, Cristina Bohorquez⁵, Ana Sánchez², Carmen Cámara², Eduardo López², Eugenio de Miguel² and Chamaida Plasencia-Rodríguez², ¹Hospital Universitario La Paz, Miranda de Ebro, Castilla y Leon, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³Rheumatology Unit, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ⁴Hospital La Paz, Madrid, Spain, ⁵La Paz University Hospital, Alcalá De Henares, Spain
Background/Purpose: Rheumatoid factor (RF), an autoantibody targeting the Fc portion of IgG, is one of the most studied biomarkers in rheumatoid arthritis (RA). High RF…
Abstract Number: 1040 • ACR Convergence 2025
Impact of Clinical Pharmacist-Directed Patient Education on Medication Adherence and Clinical Outcomes in Patients with Inflammatory Arthritis
Cristina Hurley¹, Megha Kotha², Jisna Paul³ and Jeff Barbee⁴, ¹Carilion Clinic, Roanoke, VA, ²Ohio State University, Columbus, OH, ³Division of Rheumatology and Immunology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, Columbus, OH, ⁴Ohio State University Wexner Medical Center, Columbus
Background/Purpose: This study assesses the impact of a clinical pharmacist-directed intervention on medication adherence and clinical outcomes in patients with rheumatoid arthritis, psoriatic arthritis, and…
Abstract Number: 0795 • ACR Convergence 2025
Molecular Stratification of Rheumatoid Arthritis Patients by Multi-Omics Integration Reveals Disease Status and Predictors of Therapeutic Response
Ismael Sanchez-Pareja¹, Daniel Toro², Carlos Pérez Sánchez³, Laura muñoz-Barrera¹, Tomás Cerdó¹, Elena Moreno-Caño⁴, Sagrario Corrales¹, Lydia Formanti Alonso⁵, Rafaela Ortega-Castro⁶, Jerusalén Calvo⁵, Lourdes Ladehesa⁷, Concepción Aranda-Valera⁵, M Carmen Abalos-Aguilera⁸, Christian Merlo-Ruiz⁸, MARIA ANGELES AGUIRRE ZAMORANO¹, Marta Alarcon-Riquelme⁹, Alejandro Escudero Contreras⁵ and Chary López pedrera¹⁰, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ²GENYO / Karolinska Institutet, Granada / Stockholm, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ⁴IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁵IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁷IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁹Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain
Background/Purpose: To characterize molecular profiles of RA patients through multi-omics integration and evaluate their associations with disease status and therapeutic response to csDMARDs, TNF inhibitors…
Abstract Number: 0478 • ACR Convergence 2025
Racial and Ethnic Disparities in DMARD Use and in Medicare Part B-Covered Options Among Medicare Beneficiaries with Late-Onset Rheumatoid Arthritis
ashkan ara¹, John FitzGerald² and Susan Ettner², ¹UCLA Health, Los Angeles, CA, ²UCLA, Los Angeles, CA
Background/Purpose: Biologic and targeted synthetic DMARDs can substantially improve the quality of life for Medicare beneficiaries with rheumatoid arthritis (RA). However, racial and ethnic disparities…
Abstract Number: 0035 • ACR Convergence 2025
Clinical and Transcriptomic Heterogeneity in Patients With RA: A Multi-Centric International Study of Anti-TNF Response
Maryna Borshchivska¹, Thibault Helleputte¹, Laurent Meric de Bellefon², Silvana di Romana³, Elsa Vieira-Sousa⁴, Vasco Romão⁴, João Eurico Fonseca⁵, Alla Ishchenko⁶, Patrick Verschueren⁶, Ruth Wittoek⁷, Peggy jacques⁷, Dirk Elewaut⁸, Bernard Lauwerys⁹ and Patrick Durez¹⁰, ¹DNAlytics, Louvain-la-Neuve, Belgium, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Belgium, ³Department of Rheumatology, Saint Pierre University Hospital, Brussels, Belgium, ⁴Faculdade Medicina, Universidade de Lisboa, ULS Santa Maria, Centro Académico Medicina de Lisboa, Lisboa, Portugal, ⁵Faculdade Medicina, Universidade de Lisboa, ULS Santa Maria, Centro Académico Medicina de Lisboa, Lisboa, Lisboa, Portugal, ⁶Rheumatology, University Hospital Leuven and Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium, ⁷VIB Center for Inflammation Research, Ghent University and Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁸VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ⁹Systemic and Inflammatory Rheumatic Diseases Section, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium, ¹⁰Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Brussels Hoofdstedelijk Gewest, Belgium

Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that can lead to joint damage and disability. Although methotrexate is the standard first-line treatment, about…
Abstract Number: 2543 • ACR Convergence 2025
Severe Visual Impairment in Behçet Syndrome in Time: A Comparison of Four Time Periods
Mustafa Erdogan¹, Koray Tascilar², Yagmur Ersoya³, Alp Ozcan⁴, Mert Gurcan⁴, Talal Ammar⁴, Sinem Nihal Esatoglu⁵, Yesim Ozguler⁵, Gulen Hatemi⁵ and Hasan Yazici⁶, ¹Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Department of Internal Medicine, Division of Rheumatology / Marmara University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Friedrich Alexander University of Erlangen Nuremberg, Universitätsklinikum Erlangen Department of Medicine ³, Rheumatology and Immunology, Erlangen, Germany, ³Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Department of Internal Medicine, Istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁶Academic Hospital, Istanbul, Turkey
Background/Purpose: There is consensus that the visual prognosis in Behçet syndrome (BS) uveitis has considerably improved in time (1-3). We wanted to better quantitate this…
Abstract Number: 2195 • ACR Convergence 2025
Enhancing MTX and LEF Safety for Immunosuppressed Women of Childbearing Age with Rheumatic Diseases
Angela Bobak¹, Rhea Sharma², Jordan Jackson³, Maritza Nary², Andrea Berger⁴, Lifang Zhang⁴ and Jonida Cote⁵, ¹Geisinger Medical Center Rheumatology Fellowship, Danville, PA, ²Geisinger Medical Center Internal Medicine Residency, Danville, PA, ³Geisinger Medical Center Medicine-Pediatrics Residency, Danville, PA, ⁴Geisinger Health System, Danville, PA, ⁵Geisinger Health System, Wilkes-Barre, PA
Background/Purpose: The rates of contraceptive counseling and treatment in immunosuppressed women of childbearing age remain low in the United States, despite ACR's Reproductive Health Guidelines…
Abstract Number: 1465 • ACR Convergence 2025
Sustainability of Clinical Response Through 2 Years Among Upadacitinib-Treated Patients With Axial Spondyloarthritis: Data From the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
Victoria Navarro-Compan¹, Philip J. Mease², Lianne S. Gensler³, Martin Rudwaleit⁴, Yael Klionsky⁵, Jayne Stigler⁶, Erin Mancl⁷, Shirley Chen⁸, Jamie Urbanik⁹ and Xenofon Baraliakos¹⁰, ¹Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Bielefeld University, Medical School and University Medical Centre OWL, Klinikum Bielefeld, Department of Rheumatology, Bielefeld, Germany, ⁵Division of Rheumatology, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, ⁶AbbVie, Round Lake, IL, ⁷AbbVie, Chicago, IL, ⁸AbbVie, Somerset, NJ, ⁹AbbVie, Grayslake, IL, ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Treatment with the oral JAK inhibitor upadacitinib (UPA) has shown efficacy and safety in patients with active axial spondyloarthritis (axSpA), including both radiographic (r-axSpA,…
Abstract Number: 1321 • ACR Convergence 2025
Efficacy and safety of janus kinase inhibitors in diffuse interstitial lung disease in rheumatoid arthritis. Systematic review
Olga Compán¹, Marta Ibañez², Olga Martínez³, Carolina Cristina Chacón⁴, Ricardo López Pérez³, Borja Felices López³, Belén Miguel Ibáñez³, Laura Blanco⁴, Sergio Cimadevila Santiago³, Ana Isabel Turrión Nieves³, Manuel Cipriano Martin Martinez³, Cristina Hidalgo Calleja⁴, Carlos Montilla⁴ and Susana Gómez⁴, ¹Rheumatology Service, University Hospital of Salamanca, Carbajosa de la Sagrada, ³⁷¹⁹¹, Spain, ²Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ³Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ⁴Rheumatology Service, University Hospital of Salamanca, Salamanca, Castilla y Leon, Spain
Background/Purpose: Interstitial lung disease (ILD) is a relatively common serious extra-articular complication in rheumatoid arthritis (RA). Although there have been great advances, we do not…
Abstract Number: 1025 • ACR Convergence 2025
Association Between Rural-Urban Clinics and the Management of Adult Rheumatoid Arthritis in the United States
Megan Lorenz, Paxten Wahlund, Henry Elsenpeter, Abe Sahmoun and James Beal, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND
Background/Purpose: Disease modifying anti-rheumatic drugs (DMARDs) improve symptom management and outcomes in rheumatoid arthritis (RA). While residence may influence management strategies and access to care,…
Abstract Number: 0790 • ACR Convergence 2025
Diabetes Risk in Psoriasis Patients Treated with Biologic Disease-Modifying Antirheumatic Drugs: Target Trial Emulation Using Nationwide Data
Arjun Mahajan¹, David Bates², Vinod Nambudiri³, Avery LaChance², Jeffrey Sparks⁴ and Evan Piette³, ¹Harvard Medical School, Boston, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Harvard Medical School, Boston, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Psoriasis is a chronic inflammatory skin disease associated with increased risk of metabolic complications, such as diabetes mellitus. However, the impact of specific biologic…
Abstract Number: 0473 • ACR Convergence 2025
A Phase 2b Dose-Ranging Study of Peresolimab for Adults with RA
Jay Tuttle¹, Kirstin Griffing², Mark Genovese², Hyungmin Rha², So Young Park², Pia Yachi¹, Ajay Nirula¹, LANCE PFEIFER², Tami Jo Rayle², Jesus Abraham Simón-Campos³, Clifton Bingham⁴, Kevin Winthrop⁵, Daniel Aletaha⁶, Iain McInnes⁷, Yu Xue⁸, Yoshiya Tanaka⁹, Roy Fleischmann¹⁰, Paul Emery¹¹ and Michael Weinblatt¹², ¹Lilly Biotechnology Center, San Diego, CA, ²Eli Lilly and Company, Indianapolis, IN, ³Köhler & Milstein Research, UADY School of Medicine, Merida, Yucatan, Mexico, ⁴Johns Hopkins University, Baltimore, MD, ⁵Oregon Health & Science University, Portland, OR, ⁶Medical University Vienna, Wien, Austria, ⁷University of Glasgow, Glasgow, United Kingdom, ⁸Huashan Hospital, Fudan University, Shanghai, China (People's Republic), ⁹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁰Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ¹¹University of Leeds, Leeds, England, United Kingdom, ¹²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Peresolimab, a humanized IgG1 mAb, activates programmed cell death protein 1. In a phase 2a study, peresolimab demonstrated efficacy in participants (pts) with RA…

« Previous Page
1
…
3
4
5
6
7
…
48
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].